Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms SURMOUNT-J
- Sponsors Eli Lilly and Company
- 07 Aug 2023 Status changed from active, no longer recruiting to completed.
- 04 Feb 2022 Planned End Date changed from 17 Jul 2023 to 30 Jun 2023.
- 04 Feb 2022 Planned primary completion date changed from 17 Jul 2023 to 30 Jun 2023.